A detailed history of 1832 Asset Management L.P. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, 1832 Asset Management L.P. holds 4,630 shares of VRTX stock, worth $2.33 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,630
Previous 5,780 19.9%
Holding current value
$2.33 Million
Previous $2.42 Million 10.18%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$392.81 - $485.53 $451,731 - $558,359
-1,150 Reduced 19.9%
4,630 $2.17 Million
Q1 2024

May 14, 2024

SELL
$407.69 - $446.08 $208,737 - $228,392
-512 Reduced 8.14%
5,780 $2.42 Million
Q4 2023

Feb 13, 2024

BUY
$343.0 - $410.68 $264,110 - $316,223
770 Added 13.94%
6,292 $2.56 Million
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $1.87 Million - $2 Million
5,522 New
5,522 $1.92 Million
Q2 2023

Aug 11, 2023

SELL
$314.42 - $351.91 $504,958 - $565,167
-1,606 Reduced 25.52%
4,688 $1.65 Million
Q1 2023

May 12, 2023

SELL
$283.23 - $323.1 $337,043 - $384,489
-1,190 Reduced 15.9%
6,294 $1.98 Million
Q4 2022

Feb 14, 2023

SELL
$285.76 - $321.48 $11.8 Million - $13.3 Million
-41,441 Reduced 84.7%
7,484 $2.16 Million
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $64,623 - $72,105
236 Added 0.48%
48,925 $14.2 Million
Q2 2022

Aug 15, 2022

BUY
$234.96 - $292.55 $11.4 Million - $14.2 Million
48,689 New
48,689 $13.7 Million
Q1 2022

May 16, 2022

SELL
$221.42 - $260.97 $0 - $0
0 Closed
0 $0
Q4 2021

Feb 15, 2022

SELL
$177.01 - $223.45 $14.9 Million - $18.8 Million
-84,040 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$181.39 - $202.99 $10.4 Million - $11.6 Million
-57,165 Reduced 40.48%
84,040 $15.4 Million
Q2 2021

Aug 16, 2021

BUY
$187.49 - $221.1 $23.7 Million - $27.9 Million
126,205 Added 841.37%
141,205 $27.4 Million
Q1 2021

May 17, 2021

SELL
$207.02 - $241.31 $7.31 Million - $8.52 Million
-35,300 Reduced 70.18%
15,000 $3.21 Million
Q4 2020

Feb 16, 2021

SELL
$207.01 - $276.09 $150 Million - $200 Million
-724,100 Reduced 93.5%
50,300 $11.7 Million
Q3 2020

Nov 16, 2020

SELL
$255.65 - $303.1 $74.2 Million - $88 Million
-290,200 Reduced 27.26%
774,400 $209 Million
Q2 2020

Aug 14, 2020

BUY
$225.48 - $295.8 $12.3 Million - $16.2 Million
54,700 Added 5.42%
1,064,600 $304 Million
Q1 2020

May 26, 2020

BUY
$199.77 - $247.81 $202 Million - $250 Million
1,009,500 Added 252375.0%
1,009,900 $233 Million
Q1 2020

May 14, 2020

SELL
$199.77 - $247.81 $135 Million - $167 Million
-675,600 Reduced 99.94%
400 $96,000
Q4 2019

Feb 14, 2020

BUY
$166.71 - $223.91 $79.6 Million - $107 Million
477,600 Added 240.73%
676,000 $147 Million
Q3 2019

Nov 14, 2019

BUY
$166.23 - $187.09 $27.3 Million - $30.7 Million
164,200 Added 480.12%
198,400 $32.4 Million
Q2 2019

Aug 14, 2019

SELL
$164.61 - $190.37 $28.5 Million - $33 Million
-173,300 Reduced 83.52%
34,200 $6.12 Million
Q1 2019

May 15, 2019

SELL
$163.73 - $194.7 $80.6 Million - $95.8 Million
-492,100 Reduced 70.34%
207,500 $36.8 Million
Q4 2018

Feb 14, 2019

SELL
$151.91 - $192.21 $31.1 Million - $39.4 Million
-204,925 Reduced 22.66%
699,600 $114 Million
Q3 2018

Nov 14, 2018

BUY
$167.73 - $192.74 $119 Million - $136 Million
708,025 Added 360.32%
904,525 $172 Million
Q2 2018

Aug 14, 2018

SELL
$145.72 - $169.96 $120 Million - $140 Million
-824,000 Reduced 80.74%
196,500 $32.6 Million
Q1 2018

May 15, 2018

BUY
$151.6 - $177.13 $5.97 Million - $6.98 Million
39,400 Added 4.02%
1,020,500 $165 Million
Q4 2017

Feb 14, 2018

BUY
$137.28 - $155.55 $9.66 Million - $11 Million
70,398 Added 7.73%
981,100 $145 Million
Q3 2017

Nov 14, 2017

BUY
$148.13 - $162.24 $135 Million - $148 Million
910,702
910,702 $133 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track 1832 Asset Management L.P. Portfolio

Follow 1832 Asset Management L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of 1832 Asset Management L.P., based on Form 13F filings with the SEC.

News

Stay updated on 1832 Asset Management L.P. with notifications on news.